REBECCA RAYMOND: Open Payments
NPI 1811600752 · SPOKANE VALLEY, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,862 in 86 payments from 10 companies in 2025. Trend: 2023 $119 · 2024 $1,206 · 2025 $2,862
Food & beverage: $2,690Education: $172
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 11 | $602 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $559 |
| Teva Pharmaceuticals USA, Inc. | 17 | $527 |
| Alkermes, Inc. | 11 | $324 |
| ABBVIE INC. | 8 | $244 |
| Otsuka America Pharmaceutical, Inc. | 12 | $229 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 1 | $104 |
| Axsome Therapeutics, Inc. | 3 | $83 |
| Supernus Pharmaceuticals, Inc. | 1 | $66 |
Products named: INVEGA SUSTENNA, CAPLYTA, ARISTADA, VRAYLAR, UZEDY, AUSTEDO XR, REXULTI, COBENFY.
Industry payments across WA — which companies pay providers there.
